Across the recent three months, 12 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:APLS), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 1 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 2 | 0 | 0 |
| 3M Ago | 6 | 0 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $76.17, a high estimate of $100.00, and a low estimate of $46.00. A 6.77% drop is evident in the current average compared to the previous average price target of $81.70.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of...
Login or create a forever free account to read this news
Sign up/Log in
